Activating robust immunity to tumor-associated antigens:mechanisms and biology

激活对肿瘤相关抗原的强大免疫力：机制和生物学

• 批准号: 8021006
• 负责人: Edith M Janssen
• 金额: $ 30.19万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8021006
• 关键词: Adjuvant; Anti-Inflammatory Agents; Anti-inflammatory; Antigen Presentation; Antigens; Apoptotic; Autoimmunity; Autologous Tumor Cell; Biology; CD8B1 gene; Cancer Vaccines; Cell Count; Cell Death; Cells; Chemicals; Clinical; Cross Presentation; Cross-Priming; DNA; Data; Dendritic Cells; Development; Equilibrium; Feedback; Goals; Homeostasis; IFNAR1 gene; Immune; Immune response; Immune system; Immunity; Immunization; Immunosuppressive Agents; In Vitro; Individual; Inflammatory; Interferons; Kinetics; Ligands; Malignant Neoplasms; Memory; Modeling; Molecular; Mus; Neoplasm Metastasis; Normal tissue morphology; Nucleotides; Predisposition; Prevention; Preventive; Process; Production; RNA; RNA Interference; Recurrence; Role; Signal Pathway; Structure; T cell anergy; T cell response; T-Cell Activation; T-Lymphocyte; Therapeutic; Tissues; Tumor Antigens; Vaccination; Work; autocrine; base; cell type; cytokine; design; insight; lymph nodes; neoplastic cell; novel; prevent; public health relevance; receptor; response; restoration; sensor; tumor; uptake; vaccination strategy

DESCRIPTION (provided by applicant): Therapeutic cancer vaccines are intended to drive specific activation of the immune system for therapy of existing malignancies or prevention of their recurrence. This requires powerful vaccination strategies, due to the preexisting immunosuppressive mechanisms orchestrated by the tumor. Theoretically, vaccination with apoptotic autologous tumor cells represents a particularly promising way to target the greatest number of potential antigens without the need for their individual identification. However, the sensing and clearance of apoptotic cells is generally considered to be a non-inflammatory or even tolerizing process. The prevailing view has been that apoptotic cells generated by normal tissue turnover are captured by dendritic cells (DCs) that migrate to local lymph nodes, where they induce T cell tolerance, T cell anergy, or T cell deletion in order to maintain tissue homeostasis and prevent autoimmunity in the host. We recently identified a novel DC subset (nDC), that, in contrast with other cross-presenting and cross-tolerizing DC subsets, potently (cross-)primes both CD4+ and CD8+T cells to cell-associated antigens after uptake of apoptotic material. The potent adjuvant activity of the nDC is largely dependent on their production of type I IFN after interacting with apoptotic cells. T cells primed by nDC display a greater capacity for primary expansion, cytokine production, and memory formation on a per cell basis than those primed by other DC subsets. As a consequence, these nDC are extremely potent in the induction of protective anti- tumor responses in both vaccination and therapeutic settings when exposed to apoptotic tumor cells. The central hypothesis underlying our proposed studies is that type I IFN production by nDC exposed to apoptotic cells is critical for nDC function and their subsequent priming of protective T cell responses to cell-associated antigens. The long-term goals of this work are two-fold: (1) definition of the molecular and cellular mechanisms in DCs that balance the pro- and anti-inflammatory immune response to self after cell death; and (2) translational exploitation of these mechanistic insights in order to devise effective therapeutic and preventive cancer vaccines. PUBLIC HEALTH RELEVANCE: Vaccination with apoptotic autologous tumor cells represents a particularly promising way to target the greatest number of potential antigens without the need for their individual identification. However, Cross- presentation of cell-associated antigens from apoptotic cells by DC generally leads to the induction of T cell tolerance. We have identified a new DC subset that is capable to prime T cells to cell associated antigen. In this project we will define the molecular and cellular mechanisms in these DCs that confer the T cell priming capacity in order to translational exploit of these mechanistic insights for the design of effective therapeutic and preventive cancer vaccines. .

描述(由申请人提供)：治疗性癌症疫苗旨在促进免疫系统的特定激活，用于治疗现有的恶性肿瘤或防止其复发。由于肿瘤预先存在的免疫抑制机制，这需要强有力的疫苗接种策略。从理论上讲，用自体肿瘤细胞进行凋亡免疫是一种特别有希望的方法，可以在不需要个别鉴定的情况下，针对最大数量的潜在抗原。然而，凋亡细胞的感知和清除通常被认为是一个非炎症性甚至耐受性的过程。流行的观点认为，正常组织更新产生的凋亡细胞被树突状细胞(DC)捕获，树突状细胞(DC)迁移到局部淋巴结，在那里它们诱导T细胞耐受、T细胞无能或T细胞缺失，以维持组织动态平衡，防止宿主的自身免疫。我们最近发现了一种新的DC亚群(NDC)，与其他交叉呈递和交叉耐受的DC亚群不同，它在摄取凋亡物质后，有效地(交叉)启动CD4+和CD8+T细胞对细胞相关抗原的激活。NDC的有效佐剂活性在很大程度上依赖于它们与凋亡细胞相互作用后产生的I型干扰素。与其他DC亚群相比，NDC诱导的T细胞在原代扩增、细胞因子产生和记忆形成方面表现出更大的能力。因此，当这些NDC暴露在凋亡的肿瘤细胞中时，在疫苗接种和治疗环境中都非常有效地诱导保护性抗肿瘤反应。我们提出的研究的中心假设是，暴露在凋亡细胞中的NDC产生I型干扰素对NDC的功能及其随后启动保护性T细胞对细胞相关抗原的反应至关重要。这项工作的长期目标有两个：(1)定义DC中平衡细胞死亡后对自身的促炎和抗炎免疫反应的分子和细胞机制；(2)翻译利用这些机制的见解，以设计有效的治疗和预防癌症疫苗。 与公共卫生相关：用凋亡的自体肿瘤细胞接种疫苗是一种特别有希望的方法，可以在不需要个别鉴定的情况下针对最大数量的潜在抗原。然而，DC交叉提呈来自凋亡细胞的细胞相关抗原通常会导致T细胞耐受的诱导。我们已经确定了一种新的DC亚群，它能够激活T细胞与细胞相关抗原。在这个项目中，我们将定义这些DC中赋予T细胞启动能力的分子和细胞机制，以便翻译利用这些机制来设计有效的治疗和预防癌症疫苗。。